Company / Return on Assets (ROA)
Oric Pharmaceuticals, Inc. Return on Assets (ROA) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-31.7%
FY2025
5-year range
-46.6% / -26.4%
FY2021-FY2025
Trend
+32.1%
vs FY2024
Sector context
#137 of 213
Health Care
What the data says
At -31.7%, Oric Pharmaceuticals, Inc.'s return on assets (roa) ranks #137 of 213 in the Health Care sector. Return on Assets (ROA) returned to growth in FY2025 after 4 years of decline, reaching -31.7%.
Based on SEC 10-K filings.
-31.7% in FY2025 with a 5-year CAGR of -7.0%.
Improved from -40.0% to -31.7% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +4.4pp
- 5-Year Change
- -7.0pp
- 10-Year Change
- -
Sector benchmark
#137 of 213 in Health CareTop 64% of 213This company -31.7% Sector average -24.1%
▼
-31.2% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 32.1% year-over-year.
- Currently 7.5pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
- Lowest return on assets (roa) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -31.7% | +32.1% |
| FY2024 | -46.6% | -16.7% |
| FY2023 | -40.0% | -10.8% |
| FY2022 | -36.1% | -36.8% |
| FY2021 | -26.4% | -6.9% |
| FY2020 | -24.6% | +13.7% |
| FY2019 | -28.6% | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026